+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 75Years
FEMALE
ID06713161

Using Tumor-Targeted NIR-II Fluorescent Molecular Probes to Identify Breast Cancer Tissue and Sentinel Lymph Node Metastases

Led by Yunnan Cancer Hospital · Updated on 2024-12-03

40

Participants Needed

1

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new technology using tumor-targeted near-infrared-II NIR-II fluorescent molecular probes to identify breast cancer tissue and assess sentinel lymph node SLN metastasis during breast-conserving surgery. This approach aims to improve the accuracy of tumor boundary detection and SLN metastatic status, which is important to reduce the need for second surgeries and to guide the extent of axillary lymph node dissection. The study is observational and focuses on confirming the accuracy of fluorescence imaging compared to pathological diagnosis. During surgery, fresh breast cancer tissue and SLNs will be soaked in the NIR-II probe incubation solution at different concentrations and incubation times. After rinsing and drying, fluorescence imaging is performed using the Digital Precision Medicine DPM NIR-II system to identify tumor areas and distinguish metastatic from normal SLNs. The imaging results will be correlated with pathological findings to assess the probes diagnostic accuracy. Participants will undergo surgical treatment as clinically indicated, with the additional step of their excised tissues being incubated and imaged with the NIR-II probe during the operation. Researchers will measure outcomes such as CXCR4 expression in tumors, dye uptake by tissues, and false positive rates of the probe over a two-year period. Safety and diagnostic accuracy will be monitored through pathological examination, and participant involvement includes consenting, surgery, tissue imaging, and follow-up assessments lasting until study completion.

CONDITIONS

Brief Title

Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status

Research Team

Y

Yuanyuan Zhu,Doctor

W

Weiling Chen, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here